PROKIDNEY CORP. (PROK) Form 10-Q — Aug 10, 2026
ProKidney's Q2 2026 10-Q discloses substantial doubt about the company's ability to continue as a going concern, with cash and marketable securities of $181.6 million at June 30, 2026 deemed insufficient to fund obligations for the next 12 months. Management expects existing resources to fund operations only into mid-2027. Quarterly revenue was just $150,000, entirely rental income, as the company remains pre-commercial with no approved products. Net loss attributable to Class A stockholders widened to $28.4 million from $16.6 million a year ago, driven by a $10.2 million increase in R&D spending on the ongoing Phase 3 PROACT 1 trial.
Key figures
- Revenue
- $150,000 in Q2 2026; $376,000 in H1 2026 (rental income only, no product sales)
- Net Income
- -$46.4 million Q2 2026 net loss before noncontrolling interest; -$28.4 million attributable to Class A stockholders (vs -$16.6 million in Q2 2025)
- Total Assets
- 249016000
- Cash Position
- 74868000
- Shares Outstanding
- 208,926,941 Class A and 93,395,714 Class B as of August 10, 2026
- Cash runway
- into mid-2027
- Atm total capacity
- 200000000
- Q2 2026 ga expense
- 12428000
- Q2 2026 rnd expense
- 36095000
- Marketable securities
- 106696000
- Atm remaining capacity
- 175000000
- Phase3 target enrollment
- 470
- Surrogate endpoint readout
- Q2 2027
- Confirmatory endpoint readout
- second half of 2029
- Nci economic interest percent
- 32.0%
- Cash plus marketable securities
- 181564000
- Redeemable noncontrolling interest
- 1106370000
- Accelerated approval analysis patients
- 320
Price after filing
Close on the filing date to close N calendar days later (from $1.64). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.